FIELD: biotechnology; medicine.
SUBSTANCE: monoclonal antibody or its antigen-binding fragment, which specifically binds to IL-4Rα (subunit of IL-4Rα interleukin receptor 4). The invention also relates to nucleic acids encoding the said antibody, expression vectors, host cells and methods of their production, methods of producing antibodies of the invention, pharmaceutical compositions containing an antibody of the invention, pharmaceutical compositions containing an antibody of the invention and other therapeutically active compounds, methods of treatment of IL-4Rα mediated diseases or disorders, uses of the antibodies or pharmaceutical compositions thereof for the treatment of IL-4Rα mediated diseases or disorders, and uses of the antibodies of the invention and other therapeutically active compounds for the treatment of IL-4Rα mediated diseases or disorders.
EFFECT: obtaining monoclonal antibody or its antigen-binding fragment which specifically binds to 4Rα (GD2 ganglioside).
41 cl, 8 dwg, 6 tbl, 12 ex
| Title | Year | Author | Number |
|---|---|---|---|
| ANTIBODY TO PD-L1, ITS ANTIGEN-BINDING FRAGMENT, AND THEIR PHARMACEUTICAL USE | 2019 |
|
RU2778085C2 |
| MONOCLONAL ANTIBODY OR ANTIGEN-BINDING FRAGMENT THEREOF, WHICH SPECIFICALLY BINDS TO BCMA, AND USE THEREOF | 2022 |
|
RU2820350C2 |
| ANTIBODIES WHICH BIND TO SORTILIN AND INHIBIT THE BINDING OF PROGRANULIN | 2016 |
|
RU2735639C2 |
| ANTIBODY TO B7-H4, ITS ANTIGEN-BINDING FRAGMENT AND ITS PHARMACEUTICAL USE | 2019 |
|
RU2792748C2 |
| PROTEIN BINDING WITH NKG2D, CD16 AND WITH TUMOR-SPECIFIC ANTIGEN | 2018 |
|
RU2788531C2 |
| TRISPECIFIC BINDING PROTEINS, RELATED METHODS AND VERSIONS OF USE THEREOF | 2020 |
|
RU2822200C2 |
| TUMOR-TARGETED AGONISTIC CD28-ANTIGEN-BINDING MOLECULES | 2019 |
|
RU2808030C2 |
| RGMa BINDING PROTEIN AND ITS USE | 2016 |
|
RU2809500C2 |
| PROTEINS BINDING NKG2D, CD16 AND TUMOUR-ASSOCIATED ANTIGEN | 2018 |
|
RU2816716C2 |
| ANTIBODIES BINDING TO GPRC5D | 2019 |
|
RU2797268C2 |
